Related Experiment Videos
Statin use following intracerebral hemorrhage: a decision analysis
M Brandon Westover1, Matt T Bianchi, Mark H Eckman
1Massachusetts General Hospital Stroke Research Center, 175 Cambridge Street, Boston, MA 02114, USA.
Insights
For patients with a history of intracerebral hemorrhage (ICH), avoiding statins may be beneficial. This is especially true for those with lobar ICH, where statin avoidance improved life expectancy.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Statins are widely used for preventing ischemic events.
- A recent trial indicated a potential increased risk of intracerebral hemorrhage (ICH) with statin use.
- The balance of risks and benefits for patients with prior ICH remains unclear.
Observation:
- A Markov decision model evaluated statin therapy in patients with prior ICH.
- The model assessed impacts on quality-adjusted life-years, considering hemorrhage location and cardiovascular risks.
- Statin-associated ICH risk was a key variable.
Findings:
- Avoiding statins was favored across various parameters, especially for lobar ICH survivors.
- In lobar ICH survivors without prior cardiovascular events, avoiding statins increased life expectancy by 2.2 QALYs.
- Even with high cardiovascular event risks, statin avoidance was often preferred for lobar ICH patients.
Implications:
- Statin therapy should be carefully considered for patients with a history of ICH.
- Lobar ICH location significantly influences the risk-benefit calculation, often favoring statin avoidance.
- These findings may impact clinical guidelines for statin prescription in high-risk populations.
Context:
Statins are widely prescribed for primary and secondary prevention of ischemic cardiac and cerebrovascular disease. Although serious adverse effects are uncommon, results from a recent clinical trial suggested increased risk of intracerebral hemorrhage (ICH) associated with statin use. For patients with baseline elevated risk of ICH, it is not known whether this potential adverse effect offsets the cardiovascular and cerebrovascular benefits.
Objective:
To address the following clinical question: Given a history of prior ICH, should statin therapy be avoided?
Design:
A Markov decision model was used to evaluate the risks and benefits of statin therapy in patients with prior ICH.
Main Outcome Measure:
Life expectancy, measured as quality-adjusted life-years. We investigated how statin use affects this outcome measure while varying a range of clinical parameters, including hemorrhage location (deep vs lobar), ischemic cardiac and cerebrovascular risks, and magnitude of ICH risk associated with statins.
Results:
Avoiding statins was favored over a wide range of values for many clinical parameters, particularly in survivors of lobar ICH who are at highest risk of ICH recurrence. In survivors of lobar ICH without prior cardiovascular events, avoiding statins yielded a life expectancy gain of 2.2 quality-adjusted life-years compared with statin use. This net benefit persisted even at the lower 95% confidence interval of the relative risk of statin-associated ICH. In patients with lobar ICH who had prior cardiovascular events, the annual recurrence risk of myocardial infarction would have to exceed 90% to favor statin therapy. Avoiding statin therapy was also favored, although by a smaller margin, in both primary and secondary prevention settings for survivors of deep ICH.
Conclusions:
Avoiding statins should be considered for patients with a history of ICH, particularly those cases with a lobar location.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:17Hemorrhagic Stroke l: Introduction
01:29Hemorrhagic Stroke ll: Pathophysiology
01:28Acute Coronary Syndrome IV: Interprofessional Care